Advanced Search

2022 Vol. 4, No. 4

Preplanned Studies
Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
Dan Wu, Yanyang Zhang, Lin Tang, Fuzhen Wang, Ying Ye, Chao Ma, Hui Zheng, Wenzhou Yu, Lei Cao, Yifan Song, Abuduwaili Reyimu, Xiaoxiao Zhang, Haifeng Wang, Yifei Nie, Mingxia Lu, Muge Qi, Jun Li, Ruolin Wang, Kaichao Yang, Changshuang Wang, Lawrence Everett Rodewald, Geroge Fu Gao, Zhijie An, Zundong Yin
2022, 4(4): 57-65. doi: 10.46234/ccdcw2022.009
Abstract(15388) HTML (632) PDF 281KB(63)
Abstract:
What is already known about this topic?

Effectiveness of China’s 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness against more severe coronavirus disease 2019 (COVID-19). During an outbreak in Guangdong, inactivated vaccine effectiveness (VE) against the Delta variant was 70% for symptomatic infection and 100% for severe COVID-19. However, separate or combined VE estimates for the two inactivated vaccines against Delta are not available.

What is added by this report?

In an outbreak that started in a hospital, VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant were 51%, 61%, and 82%. Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%. VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar, and partial vaccination was ineffective.

What are the implications for public health practice?

Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Completion of the completed primary vaccination with two doses is necessary for protection from Delta.

Willingness of the General Public to Receive A COVID-19 Vaccine Booster — China, April–May 2021
Xiaoxiao Wang, Leyuan Liu, Minyue Pei, Xiaoguang Li, Nan Li
2022, 4(4): 66-70. doi: 10.46234/ccdcw2022.013
Abstract(8523) HTML (627) PDF 223KB(35)
Abstract:
What is already known about this topic?

A coronavirus disease 2019 (COVID-19) vaccine booster is planned for administration to eligible individuals. Understanding the factors that influence attitudes towards the booster shot will help to identify groups that will most readily accept a booster dose.

What is added by this report?

Of the individuals polled, 75.2% reported they would receive a booster shot. Sociodemographic characteristics influencing booster vaccine acceptance included age, gender, occupation, and education. Moreover, those who had been vaccinated against influenza, who believed herd immunity would be effective against severe acute respiratory syndrome coronavirus 2, and who reported reduced anxiety after vaccination were more likely to accept a booster dose.

What are the implications for public health practice?

A booster shot of the COVID-19 vaccine could be widely accepted. Communicating about the effectiveness of the COVID-19 vaccine and the impact of infection on people’s health could help increase public willingness to get a booster dose.

Perspectives
Bubble Strategy — A Practical Solution to Return to Regular Life in the Intertwined Era of Vaccine Rollouts and Virus Mutation
Ying Shen, Da Huo, Tong Yu, Quanyi Wang
2022, 4(4): 71-73. doi: 10.46234/ccdcw2022.014
Abstract(8632) HTML (529) PDF 263KB(47)
Abstract:

For a long time, vaccination and herd immunity were considered to be the magic solution for controlling coronavirus disease 2019 (COVID-19). However, the emergence of new variants altered people’s expectations and prolonged the pandemic duration, especially the Omicron strain with substantially increased transmissibility and decreased vaccine efficacy. Therefore, we are in urgent need of a practical solution to resume regular life to some extent, while mitigating COVID-19 risks in the tight race between vaccine rollouts and virus variation. This commentary proposed that bubble strategy (or closed loop management), utilized in Tokyo 2020 Olympic Games and to be implemented in Beijing 2022 Winter Games, could serve as a novel technique of non-pharmaceutical interventions in coping with such a situation.

Notes from the Field